Ginsenoside Rg5
(Synonyms: 人参皂甙 Rg5) 目录号 : GC31706A ginsenoside with diverse biological activities
Cas No.:186763-78-0
Sample solution is provided at 25 µL, 10mM.
Ginsenoside Rg5 is a ginsenoside originally isolated from P. ginseng that has diverse biological activities, including anticancer, anti-inflammatory, neuroprotective, and antioxidant properties.1,2,3 It inhibits the growth of HeLa and MS751 cervical cancer cells (IC50s = ~2.5-10 μM) and induces apoptosis in a concentration-dependent manner.1 Ginsenoside Rg5 (5 and 10 μM) inhibits LPS-induced increases in IL-1β, TNF-α, COX-2, and inducible nitric oxide synthase (iNOS) protein levels in murine alveolar macrophages.2 It also inhibits LPS-induced increases in the number of neutrophils and protein levels of IL-1β, TNF-α, COX-2, and iNOS in lung in a mouse model of acute lung inflammation when administered at a dose of 10 mg/kg. In a rat model of Alzheimer's disease induced by streptozotocin , ginsenoside Rg5 blocks STZ-induced increases in amyloid-β accumulation in the hippocampus and cerebral cortex and prevents STZ-induced decreases in step through latency time in a passive avoidance foot-shock test in a dose-dependent manner.3
1.Liang, L.-D., He, T., Du, T.-W., et al.Ginsenoside?Rg5 induces apoptosis and DNA damage in human cervical cancer cellsMol. Med. Rep.11(2)940-946(2015) 2.Kim, T.-W., Joh, E.-H., Kim, B., et al.Ginsenoside Rg5 ameliorates lung inflammation in mice by inhibiting the binding of LPS to toll-like receptor-4 on macrophagesInt. Immunopharmacol.12(1)110-116(2012) 3.Chu, S., Gu, J., Feng, L., et al.Ginsenoside Rg5 improves cognitive dysfunction and beta-amyloid deposition in STZ-induced memory impaired rats via attenuating neuroinflammatory responsesInt. Immunopharmacol.19(2)317-326(2014)
Kinase experiment: |
HUVECs are cultured in 24-well plates overnight. The cells are changed to serum-free M199 and incubated for 1 h. The medium is removed, and cells are incubated with fresh serum-free medium containing 0.1 μM-50 mM Ginsenoside Rg5 at 37°C for 20 min followed by the addition of 50 μL (1 μCi) of [125I]IGF-1 and then further incubated for 10 min. The medium is decanted, and cell plates are washed twice with serum-free medium. Cells are lysed in 300 μL of 0.1 N NaOH solution containing 0.1% SDS, transferred to scintillation vials, and mixed with 1 mL of Ultima Gold mixture solution. Cell-associated [125I]IGF-1 is analyzed in a scintillation counter. The nonspecific binding is determined by coincubation with unlabeled IGF-1 (50 nM)[1]. |
Cell experiment: |
MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) human breast cancer cell lines are maintained using RPMI 1640 medium supplemented with 10% (vol/vol) FBS plus 100 units/mL Penicillin and Streptomycin in a 5% carbon dioxide air incubator at 37°C. Cell cytotoxicity is measured by MTT assay. Cells are seeded in 96-well tissue culture plates at the density of 0.2×104 cells per well with 100 μL medium, and are allowed to become attached for 24 h. One hundred microliters of the medium with different concentrations of Ginsenoside Rg5 (e.g., 0 μM, 25 μM, 50 μM, and 100 μM) are added to each well. At indicated times, 30 μL MTT stock solution (3 mg/mL) are added to each well. After culturing the cells at 37°C for 2 h, DMSO is added to dissolve the formazan crystals. The absorbance is read at the wavelength of 540 nm with a microplate reader[3]. |
Animal experiment: |
Mice[2]Male ICR mice (6 to 8 weeks old), weighing 25-27 g, are used. After acclimation for one week, mice are randomly assigned into 4 experimental groups with 8 mice in each group: normal control, Cisplatin control, and Cisplatin+Ginsenoside Rg5 groups (10 and 20 mg/kg, respectively). Ginsenoside Rg5 is administered intragastrically at the dose of 10 and 20 mg/kg for 10 days. On the 7th day, animals in Cisplatin control and Ginsenoside Rg5-treated groups receive a single intraperitoneal injection of Cisplatin (25 mg/kg) to induce nephrotoxicity in mice. Mice are anaesthetized with pentobarbital, subsequently sacrificed at 72 h after Cisplatin injection (Day 10). Blood samples are collected and then centrifuged at 3000 rpm to separate the serum and stored at -20 °C for determining blood urea nitrogen (BUN) and creatinine (CRE) levels. |
References: [1]. Cho YL, et al. Specific activation of insulin-like growth factor-1 receptor by ginsenoside Rg5 promotes angiogenesis and vasorelaxation. J Biol Chem. 2015 Jan 2;290(1):467-77. |
Cas No. | 186763-78-0 | SDF | |
别名 | 人参皂甙 Rg5 | ||
Canonical SMILES | C[C@@]([C@@]12C)(CC[C@@]3([H])C4(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@@H](/C(C)=C/C/C=C(C)\C)CC2)([H])[C@]3(CC[C@@H]4O[C@@](O[C@H](CO)[C@@H](O)[C@@H]5O)([H])[C@@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)C | ||
分子式 | C42H70O12 | 分子量 | 767 |
溶解度 | DMF: 10 mg/ml,DMSO: 10 mg/ml | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.3038 mL | 6.5189 mL | 13.0378 mL |
5 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL |
10 mM | 0.1304 mL | 0.6519 mL | 1.3038 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet